Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30790285 | 0.74 | — | — | |
| SCHEMBL31337161 | 0.71 | EGFR (0.33) | — | |
| SCHEMBL31061724 | 0.71 | — | — | |
| SCHEMBL30783034 | 0.67 | — | — | |
| SCHEMBL28287224 | 0.65 | — | — | |
| SCHEMBL876323 | 0.63 | EGFR (0.33) | — | |
| SCHEMBL322054 | 0.62 | CDC25B (0.31) | CDC25B | |
| SCHEMBL19207495 | 0.61 | — | — | |
| SCHEMBL30753848 | 0.61 | CDC25B (0.33) | CDC25B | |
| SCHEMBL247141 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| CN-120081848-A | Imidazo-containing pyrimidinone derivative, and preparation method and application thereof | 贵州大学 | 2025-06-03 | — | — | CN | claimed |
| EP-4554678-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-21 | — | — | EP | claimed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | claimed |
| WO-2024013205-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-18 | — | — | WO | claimed |
| CN-114106000-B | Imidazo [4,5-d ] pyrimidinone tricyclic derivative and antitumor application thereof | 中国科学院新疆理化技术研究所 | 2023-11-24 | — | — | CN | claimed |
| CN-115448921-B | Imidazolidine pyrimidinone compounds and use thereof in treatment of HsClpP mediated diseases | 四川大学 | 2023-08-01 | — | — | CN | claimed |
| CN-114106000-A | Imidazo [4,5-d ] pyrimidone tricyclic derivative and anti-tumor application | 中国科学院新疆理化技术研究所 | 2022-03-01 | — | — | CN | claimed |
| CN-113604148-A | Nano SiO2Modified quadruple hydrogen bond type self-repairing polyurethane coating and preparation method thereof | 深圳市博仲实业有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-113164618-A | Methods and compositions for treating diseases with immunostimulatory conjugates | 希沃尔拜克治疗公司 | 2021-07-23 | — | — | CN | claimed |
| US-6432642-B1 | A DETECTOR, TARGET, CLAMPS AND HYBRIDIZATION | PE CORPORATION (NY) | 2002-08-13 | — | — | US | claimed |
| EP-1155027-A2 | SYNTHESIS OF LABELLED OLIGONUCLEOTIDES ON SOLID-SUPPORTS | PE Corporation (NY) (US) | 2001-11-21 | — | — | EP | claimed |
| US-6316230-B1 | ENZYMATICALLY EXTENDING A PNA(PEPTIDE NUCLEIC ACID)-DNA CHIMERA IN PRESENCE OF TEMPLATE NUCLEIC ACID, POLYMERASE AND PRIMER EXTENSION REAGENT | APPLERA CORPORATION | 2001-11-13 | — | — | US | claimed |
| US-6316610-B2 | Hybrid stabilization | PE CORPORATION (NY) | 2001-11-13 | — | — | US | claimed |
| EP-1141387-A2 | BINARY PROBE AND CLAMP COMPOSITION AND METHODS FOR TARGET HYBRIDIZATION DETECTION | PE Corporation (NY) (US) | 2001-10-10 | — | — | EP | claimed |
| US-6297016-B1 | ENZYMATICALLY LIGATING A PEPTIDE NUCLEIC ACID-DNA CHIMERIC PROBE TO SECOND PROBE WHEN PROBES ARE HYBRIDIZED ADJACENT TO EACH OTHER ON A TEMPLATE NUCLEIC ACID | APPLERA CORPORATION | 2001-10-02 | — | — | US | claimed |
| US-20010014735-A1 | Labelled oligonucleotides synthesized on solid-supports | PE CORPORATION (NY) | 2001-08-16 | — | — | US | claimed |
| US-6255476-B1 | REACTING A LABELLED SOLID SUPPORT OF GIVEN FORMULA TO REMOVE AN ACID CLEAVABLE PROTECTING GROUP, ADDING A 5'-PHOSPHORAMIDITE, 3'-PROTECTED NUCLEOSIDE AND AN ACTIVATOR TO FROM A BOND | PE CORPORATION (NY) | 2001-07-03 | — | — | US | claimed |
| WO-2000050432-A2 | SYNTHESIS OF LABELLED OLIGONUCLEOTIDES ON SOLID-SUPPORTS | PE CORPORATION (NY) (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000041549-A2 | BINARY PROBE AND CLAMP COMPOSITION AND METHODS FOR TARGET HYBRIDIZATION DETECTION | PE CORPORATION (NY) (US) | 2000-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014735-A1 | Labelled oligonucleotides synthesized on solid-supports | NSUN2, TST, NSUN3 | CDC25B 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.